VCYT
Diagnostics & Research · Healthcare
CEO, Board Member
2021-01-01–present
Board Member
Veracyte, Inc. (VCYT)Equibles does not estimate personal net worth.
Get an email with a short summary when Veracyte, Inc. publishes a filing, an earnings call transcript or a press release.
Get VCYT alertsMarc Stapley is recorded as Board Member at Veracyte, Inc. (VCYT) since January 1, 2021 and CEO at Veracyte, Inc. (VCYT). The newest filing on record that lists Marc Stapley as CEO and Board Member at Veracyte, Inc. (VCYT) is dated April 22, 2026. Veracyte, Inc. reported in an 8-K filed June 11, 2026 that Marc Stapley was appointed director, effective June 10, 2026. Veracyte, Inc. reported in an 8-K filed June 18, 2025 that Marc Stapley was appointed director, effective June 17, 2025. Veracyte, Inc. reported in an 8-K filed June 13, 2024 that Marc Stapley was appointed director, effective June 12, 2024. The proxy statement of Veracyte, Inc. reports total compensation of $7,421,877 for Marc Stapley in fiscal 2025, including a base salary of $700,000. Disclosed compensation is on record for 5 fiscal years. Marc Stapley has spoken on 21 earnings calls and 3 other investor events across 1 company, most recently for Veracyte, Inc. on September 15, 2026. Veracyte, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Veracyte, Inc. includes Bonnie H. Anderson (Chairman), Rebecca Chambers (CFO), Christopher Hall (COO) and 7 others.
“Each of the nine nominees for director was elected to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified.”
“Each of the seven nominees for director was elected to serve until the 2026 annual meeting of stockholders and until their successors are duly elected and qualified.”
“Before I get into that, maybe I should just remind everybody about our safe harbor statement. To the extent we make forward-looking statements, you can find that in its full on our website at www.verisite.com. So, yeah, Convergent, great acquisition for us.”
“Q2 is a milestone call to the Verisite as we launched ProSigna LDT and TrueMRD, catalyzing two of our key growth opportunities and meaningfully expanding our portfolio.”
“Before we get started, I would like to remind you of our safe harbor, which can be found at Verisite.com. and that the goal of that is to cover anything we say today but with that let's move on.”
“So we look forward to updating you on our business with some really important and exciting updates over the last week or so.”
“In the first quarter, we delivered strong double-digit revenue and volume growth, exceeded our profitability expectations, and continued advancing key catalysts that position us well for long-term growth.”
2021-01-01–present
Last confirmed April 22, 2026
Start not stated–present
Last confirmed April 22, 2026
VCYT
Diagnostics & Research · Healthcare
CEO, Board Member
2021-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Veracyte, Inc. (VCYT) | Chief Executive Officer | $700,000 | $7,421,877 |
| 2024 | Veracyte, Inc. (VCYT) | Chief Executive Officer | $675,000 | $6,816,368 |
| 2023 | Veracyte, Inc. (VCYT) | Chief Executive Officer | $650,000 | $7,184,634 |
| 2022 | Veracyte, Inc. (VCYT) | Chief Executive Officer | $625,000 | $4,935,422 |
| 2021 | Veracyte, Inc. (VCYT) | Chief Executive Officer | $350,000 | $5,741,940 |